Introduction
scores in patients suffering from AD [3b, 5] . Furthermore, there is considerable evidence that cholinergic drugs affect cognitive function, including attention and memory in humans [6] and experimental animals [7] . These findings suggest that the cognitive dysfunction in AD patients is related to a decrease in the cholinergic activity in the brain; therefore, potentiation of central cholinegic activity has been proposed as a possible therapeutic approach to AD [8] .
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive deterioration of memory and cognition. Prominent histopathological features of AD include the extracellular deposition of amyloid and the accumulation of intracellular neurofibrillary tangles [1] . Remarkable degeneration occurs in various regions of the brain that play a major role in memory and cognition [2] . The most striking and consistent neurochemical change in the brains of AD patients is a marked decrease in choline acetyltransferase (ChAT) activity in the hippocampus and cerebral cortex [3] , although other neurochemical changes are also observed [4] . A significant correlation has been found between a decrease in cortical cholinergic activity and the deterioration of mental test Among agents which can enhance cholinegic activity in the brain, inhibitors of acetylcholinesterase (AChE) have been extensively studied. Various AChE inhibitors have been tested preclinically and investigated clinically; recent clinical data of several compounds have been summarized by Giacobini [9] , Benzi and Moretti [10] . As a result of these extensive efforts, three AChE inhibitors have been approved for the treatment of AD, namely, tacrine (THA), donepezil (E-2020) and rivastigmine (ENA-713) (Fig. (1 ) ). These drugs have produced significant cognitive improvements; however, the effects were only modest [10] . This is a problem of the AD therapy with AChE inhibitors. One of the reason for the moderate efficacy is attributed to their adverse peripheral effects, which are dose-limiting. This could be overcome by searching for central selective AChE inhibitors. In order to find such inhibitors, we have performed a study based on a new working hypothesis of the enzyme's active site. Our effort resulted in a discovery of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147). Pharmacological and pharmacokinetic studies have shown that TAK-147 acts selectively on the central nervous system, thus exerting ameliorating effects on cholinergic deficits without showing excessive peripheral effects.
In this review we describe a proposal of the working hypothesis, structure-activity relationships (SAR) of designed compounds, a discovery of TAK-147 and its central selectivity. We also summarize preclinical pharmacology of TAK-147 and discuss its potential use as a therapeutic drug for AD.
Structure-Activity Relationships Working Hypothesis and Design

AChE
(EC 3.1.1.7) terminates neuronal transmission at cholinergic synapses by rapid hydrolysis of acetylcholine (ACh) [11] . The catalytic center of the enzyme is composed of an esteratic and an anionic subsites [12] . In addition to the active site, a peripheral anionic site remote from the active site has been identified [13] . The X-ray crystal structure of AChE from Torpedo californica has revealed that it contains a catalytic triad, which locates at the bottom of a deep and narrow gorge surrounded by 14 aromatic amino acids [14] . With the three-dimensional structure of the enzyme in hand, the structure-based design of AChE inhibitors is possible at present.
In addition, we have recently revealed that TAK-147 enhances ChAT activity in cholinergic neurons and potentiates the action of NGF which increases ChAT activity; this suggests that the compound has NGF-like neurotrophic activity. Although an AChE inhibitor does not affect the course of AD via its primary action, the neurotrophic action of TAK-147 could be reflected clinically by slowing down the progression of the disease. Before the X-ray crystal structure determination, the binding sites were identified by kinetic, spectroscopic and chemical modifications, which has been extensively reviewed by Quinn [12] . That was the starting point of our research. The stylized diagram in the review has prompted us to propose a working hypothesis of the enzyme's active site [15] . The hypothesis, in essence, is based on an assumption that there may exist a hydrophobic binding site (HBS-2) some distance removed from the conventional catalytic subsites: an anionic as well as an esteratic subsites and, closely adjacent to these, a hydrophobic binding site (HBS-1) (Fig. (2 ) ). Compounds which can interact with both hydrophobic binding sites and the anionic site seem to have provided us with a new type of AChE inhibitors. On the basis of this working hypothesis, we
The choice of an Nalkyl-N-(ω -phenylalkyl)amino moiety, especially the Nalkyl-N-benzylamino group, was based on its similarity to miotine which is known as a potent AChE inhibitor (Fig. (1 )) [16] . 1H-Isoindole-1,3(2H)-dione (phthalimide) was chosen as the moiety which could potentially interact with HBS-2, because the phthalimide derivatives (1 ) having different carbon chain length (n in Fig. (2 ) ) could be easily prepared and would be useful for evaluating the working hypothesis.
Kleinberger and Yanai [17] . The results are expressed as the 50% inhibitory concentration (IC 50 ). The IC 50 values of physostigmine and tacrine were 220 and 300 nM, respectively.
The SAR of the phthalimide derivatives (1 ) are summarized as follows [15] . (nM) Fig. (3) . Relationship between AChE inhibition and carbon chain length (n) of the phthalimide derivatives 1a-r with various N-alkyl substituents (R).
1.
The effects on AChE inhibition of variation of the chain length (n) as well as N-alkyl substituents (R) are shown in Table 1 and Fig. (3 ) . Optimum activity was found to be associated with carbon chain length. The number of carbon atoms (n) with optimum inhibitory activities were 6 (1d: R=Me), 5 (1j: R=Et) and 4 (1n: iso-Pr and 1q: R=Pr). The potency gradually decreased either
Structure-Activity Relationships of the Phthalimide Derivatives
The measurement of AChE inhibitory activity was carried out radiometrically via the method of expected to contribute to the activity by carbamoylating the esteratic site, resulted in a sharp enhancement of inhibitory potency. The IC 50 value has been measured as about 1,000 times stronger than that of physostigmine or tacrine (1cc: IC 50 = 0.38 nM).
5.
Saturation of the benzene ring of the phthalimide moiety caused an approximately 5-fold decrease in activity (cf. 1dd vs 1s).
6.
Saturation of the phenyl ring of the benzylamino moiety led to a 7-fold loss in enzyme inhibition (cf. 1ee vs 1j).
7.
Reduction of the basicity of the benzylamino nitrogen significantly decreased the activity (cf. 1ff vs 1i).
The above results seem to support our working hypothesis which includes the following two points. The first point of the hypothesis, which may be supported by results 4, 6 and 7, is that the benzylamino moiety of 1 binds to the anionic site and to the HBS-1. These interactions correspond to those postulated for binding in the case of miotine [16b] . Results 1 and 6 may support the second point, which is that the phthalimide moiety interacts with another hydrophobic binding site (HBS-2) some distance removed from the anionic site. The distance can be estimated at a seven carbon chain length or less. Hydrophobic interactions with both HBS-1 and HBS-2 seem to be mainly π-π interactions.
Recently, some xanthone analogs bearing a benzylamino moiety were prepared by other group and found to be potent inhibitors of AChE [18] . It was reported that these compounds were designed partly on the basis of our assumption of HBS-2. According to these reports as well as our studies, the working hypothesis has been shown to be effective in the design of new type of AChE inhibitors having a benzylamino moiety. by extending or reducing the chain length. Among compounds 1a-r, 1j (n=5, R=Et) showed the most potent activity, which was greater than that shown by either physostigmine or tacrine.
Docking Analysis
2.
The effects of substituent (X) on the phthalimide moiety have been examined (Table 2) . Hydrophilic and electron-withdrawing substituents, such as NO 2 , NHAc and CONHMe, were found to enhance AChE inhibitory activity (cf. 1j, 1x, 1y vs 1s).
The X-ray analysis of AChE has revealed that ca. 40 % of the surface of the "active site gorge" is composed of 14 aromatic residues [14] . In order to define the residues involved in HBS-1 and HBS-2, docking analysis of a series of benzylamino AChE inhibitors, including the phthalimide derivatives (1 ) and TAK-147, has been carried out. 3.
As a substituent (Y) of the benzylamino moiety, a methoxy group at either meta or ortho position increased the activity (cf. 1z, 1aa vs 1j).
The enzyme-binding mode has been analyzed on the basis of the crystal structure of the Torpedo enzyme using docking programs DOCK and directed-DOCK [19] . The analyzed compounds have a
4.
Incorporation of a 3-MeNHCO 2 -group on the phenyl ring of the benzylamino moiety, which is benzylamino group at one end and a phthalimide, benzoyl or indanone moiety at the other. The binding mode of TAK-147 is shown in Fig (4 ) . The results of more than 50 compounds have indicated that the benzyl group interacts with Trp 84, which is located near the bottom of the binding pocket and is postulated to be the quaternary ammonium binding site for ACh. The other aromatic ring has been found to interact with Trp 279 at the peripheral hydrophobic site, which is also called 'peripheral anionic site' [13] . These Trp residues would correspond to HBS-1 and HBS-2. In addition, the hydrogen-bonding interaction between a carbonyl group of the inhibitor and Tyr 121 OH seems to be important for tight binding; this is also consistent with the SAR described in the following part.
Other groups have reported the binding mode of Nbenzylpiperidine inhibitors [20] . Very recently, the three-dimensional structure of a complex of donepezil with AChE from Torpedo californica was reported [21] . It is reported that donepezil interacts with both the 'anionic' subsite at the bottom of the gorge and the 'peripheral anionic site' near its entrance. These studies also suggest that Trp 84 and Trp 279 are important residues for the binding of this class of inhibitors. 
Structural Alteration for
Central Selective Inhibitors After revealing SAR of the phthalimide derivatives (1 ), we focused our attention to the transformation of the phthalimide moiety of 1 . During the course of study, the carbonyl group of the phthalimide has been suggested to be important for potent inhibition [22] . Therefore, the effect of linkage (A) on AChE inhibition was examined by preparing acyclic compounds (2a, 3-7 ) [23] . Inhibitory activity decreased in the order COCH 2 > COO > CONAc > OCH 2 > CH 2 CH 2 > CONH (Table 3 ). The keto carbonyl group exhibited the most potent inhibitory activity, which was 100 times greater than that shown by the methylene group. As previously described, the docking analysis has suggested that the carbonyl group forms a hydrogen-bonding interaction with the enzyme. Because 2a showed the most potent inhibition, the compound was chosen as a key compound for further structural alteration. Since the key compound 2a is acyclic and very flexible, we were interested in its partial conformational restriction, which is shown by arrows a-d (Fig. (5 ) ) [23] . We hoped that these ring closures might enhance in vitro inhibitory potency and influence in vivo activity including central selectivity.
indanone (8a-c) as well as the piperidine derivatives (10a,c) were equipotent with the key compounds (2a-c). The cyclohexyl phenyl ketone 9 and tetrahydroisoquinoline derivative 11 were very weak inhibitors of AChE. Closer SAR examination of compounds 2 , 8 and 10 revealed that there were differences between them concerning the effects of substituents (Y) and chain length (n). The effects on AChE inhibition were found to be as follows. In general, the ring closures indicated by arrows a and c retained potency, whereas ring closures b and d resulted in a decrease in the activity. Thus, the Selected compounds (2a,b, 8a,b and 10a,c) were evaluated in terms of central selectivity (Table 4) . An estimate of central selectivity can be obtained from the ratio of central to peripheral action: minimum dose (peripheral action) / minimum effective dose (ameliorating effect on memory impairment). Compounds were first examined for their effects on peripheral behavioral changes such as salivation, lacrimation, diarrhea and fasciculation. Most compounds were found to show fasciculation at the minimum doses. Subsequently, compounds were evaluated, at doses less than these minimum doses causing peripheral action, for their ameliorating effects on scopolamine-induced memory impairment by Tmaze alteration task. The piperidine (10a, c) and indanone derivatives (8a) as well as tacrine ameliorated memory impairment at dose ranging from 3 to 20 mg/kg po, whereas none of 2 exhibited improvement at doses up to 50 mg/kg po. In terms of central selectivity, the compounds with partial conformational restriction (8a and 10a,c) seem to have more preferable properties than the acyclic key compounds (2a, b) (Table 4 ), though they all exhibited equipotent AChE inhibition. Especially 10c showed the best ratio for central selectivity, which was slightly better than tacrine. The determination of the brain and plasma levels of 10c also suggested its good central selectivity [23] . These results indicate that the piperidine moiety is an important structural feature for central selectivity.
Structure-Activity Relationships of TAK-147 and its Analogs
Although central selectivity of 10c was found to be slightly better than that of tacrine, the selectivity still seemed insufficient as a drug candidate. In search for more central selective inhibitor than 10c, we synthesized heterocyclic derivatives 12-18, which are analogs of 10c with ring closure e (Fig. (6 ) ) [24] . These compounds were prepared by regioselective FriedelCrafts acylation of nitrogen heterocycles as a key reaction [24, 25] .
with increasing size of heterocyclic ring. Methyl substitution on the nitrogen of heterocycles enhanced the activity (cf. 12a vs 12b). The effects of substituents (Y) on the benzylamino moiety were examined: a fluoro group at meta position increased or retained the activity (cf. 12a vs 12c, 17a vs 17c).
Most compounds exhibited potent activities with IC 50 s in the 10-150 nM range (Table 5 ). Among Nunsubstituted compounds, an indoline derivative 12a (IC 50 = 20 nM) was the most potent inhibitor. The potency seemed to decrease gradually in accordance As a convenient and efficient method for evaluating compounds as central selective AChE inhibitors, we examined their inhibitory effects on apomorphineinduced circling behavior in rats with unilateral striatal lesions caused by injection of excitatory amino acid [24] . Our aim here was to find compounds that inhibit the circling behavior at doses in which they do not cause any peripheral side effects. and monkeys were 4.2 and 5.7%, respectively. The brain level of TAK-147 was much higher than that in plasma in both species, and the compound stably exists in the brain for a long time (8 to 24h). Repeated administration of TAK-147 did not result in accumulation in the peripheral organs.
Initially, to set up a dose of the experiment for each compound, these compounds were examined for their effects on peripheral behavioral changes such as salivation, lacrimation, diarrhea and fasciculation (Table  5) . Compounds were subsequently evaluated, at doses less than these doses causing peripheral action, for their inhibitory effects on the apomorphine-induced circling behavior. Among them, the benzazepine derivative 17a (TAK-147) significantly inhibited the circling behavior at 3 mg/kg po, in which it had no notable effect on peripheral cholinergic effects. Compounds 12b and 14b inhibited the circling at doses of 10 and 3 mg/kg po, respectively, although fasciculation was observed at these doses. Tacrine also inhibited the circling behavior at 10 mg/kg po. Among compounds 12-18, 17a (TAK-147) was suggested to be the most central selective inhibitor.
These results have shown that TAK-147 has high central selectivity, as demonstrated by rapid elimination from plasma and long-term existence in the brain. This pharmacokinetic property seems to be ideal for applying AChE inhibitors to the treatment of AD.
Pharmacology of TAK-147
AChE Inhibition / Effects on General Behavior in Rats
The selectivity of TAK-147 for AChE over butyrylcholinesterase (BuChE) was investigated [27] . The IC 50 value of TAK-147 for AChE was 51.2 nM. In contrast, the compound showed very weak inhibition of BuChE. Table 6 shows that TAK-147 is a highly selective inhibitor of AChE compared with tacrine and physostigmine.
Central selectivity of TAK-147 and tacrine were compared by estimating the ratio of ED 50 (peripheral action: fasciculation) over minimum effective dose (central action: ameliorating effect on diazepaminduced passive avoidance response). TAK-147 was found to be about 7 times more central selective than tacrine [24] . Plasma and brain levels of TAK-147 after oral administration of 3 mg/kg of [ 14 C] TAK-147 to rats and monkeys are shown in Fig. (7 ) [26] . The plasma concentration rapidly decreased in both rats and monkeys, and half-lives (T 1/2 ) were 2.1 and 2.3 h, respectively. The bioavailabilities of TAK-147 in rats The effects of TAK-147 on general behavior in rats were observed in detail [26] . TAK-147 produced miosis and fasciculation at relatively low doses; ED 50 s were 5 -10 mg/kg po. Lacrimation and salivation were observed only at high doses. The peripheral side effects and acute toxicity of TAK-147 were weak as compared with those of tacrine.
mild depressive symptoms to major depression [30] . It has been generally shown that cholinergic stimulants induce sedation or behavioral depression, and these effects of AChE inhibitors may exacerbate depressive syndromes and weaken the ameliorating effects on the cognitive deficits in AD [31] . TAK-147 (2 -10 mg/kg po) has shown no depressive properties in the forced swimming test; in contrast, tacrine exacerbated the behavioral depression [26] . Treatment with TAK-147 (1 -10 mg/kg po) antagonized the reserpine-induced hypothermia and ptosis in a dose-dependent manner [29] .
Ameliorating
Effects on Learning and Memory Impairment
The learning deficit observed in aged rodents is a promising model to understand the effects of aging on brain systems involved in memory function in humans [28] . Effects of repeated administration of AChE inhibitors on the water maze learning deficit in aged rats were examined (Fig.(8 ) ) [26] . TAK-147 (0.1 and 1 mg/kg po) ameliorated impairments of learning and memory in aged rats, and marked effect was observed at 1 mg/kg. Tacrine (0.5 -3 mg/kg po) did not reverse, but rather exacerbated, the impairment.
Neuronal cell loss in AD brain is not restricted to the BF cholinergic complex. The locus coeruleus, which provides noradrenergic innervation, and the raphe neucleus, which provides serotonergic (5-HT) innervation, also show severe neuronal dropout in AD [4a-c, 4e] . Dysfunction of both the norepinephrine (NE) and 5-HT nervous systems occurs in patients with AD, and it is, therefore, preferable for drugs for AD to have both cholinergic and monoaminergic characteristics. TAK-147 (3 mg/kg po) accelerated the turnover of NE, dopamine and 5-HT in the rat brain [27] . The compound also mildly inhibited the uptake of NE and 5-HT.
In addition, TAK-147 (1 -3 mg/kg po) ameliorated drug-induced impairments of learning and memory in rats [29] . Repeated administration of TAK-147 (0.3 -3 mg/kg po) also decreased learning impairment in BFlesioned rats [26] .
Effects on Reduced Brain Energy Metabolism in Aged Rats
These results suggest that TAK-147 ameliorates learning and memory impairments in various animal models at doses that it does not cause any peripheral side effects.
It has been suggested that a defect in energy metabolism may occur in AD [32] . Positron emission tomographic studies of cerebral glucose metabolism have shown that a decrease in the parietal and temporal cortices occurs early in the course of AD and may precede cognitive deficits [32a, 33] . Moreover, the reduction in cerebral glucose metabolism has shown to correlate significantly with severity of dementia [34] . Fig. (8) . Effects of TAK-147 (A) and tacrine (B) on the water maze learning deficit in F344 aged rats. Each rat underwent 4 trials a day for 3 consecutive days (3 blocks of 4 trials), and the latency before it escaped onto the platform was recorded. The task was performed at least 9 days after starting daily drug administration. Each drug was given 30 min before each session. Each value is the mean latency and the vertical bar shows the SEM. One-way ANOVA on the escape latency across training revealed that TAK-147 ameliorated the impaired learning in aged rats. Treatment with tacrine had no significant effect statistically. **P < 0.01 (Student's t-test), ## P < 0.01 (Dunnett's test), compared with the aged control. Effects of TAK-147 on cerebral energy metabolism were investigated using an in vivo 31 P magnetic resonance spectroscopy technique and the autoradiographic 2-deoxy-[ 14 C]D-glucose method in aged rats [35] . Administration of TAK-147 (0.5 and 1 mg/kg po) for 60 days reversed the reduction in the rate of local cerebral glucose utilization in a dosedependent manner, especially in the temporal cortex (Fig. (9 ) ). permeability which mimic and/or potentiate the action of NGF would be desirable.
Effects
We have recently found that TAK-147 potentiates ChAT activity in cultured rat septal cholinergic neurons in a concentration-dependent manner with an EC 50 value of 4.47 nM (Fig. (1 0 )) [38] . Other AChE inhibitors, such as tacrine, physostigmine and neostigmine, showed no effect. The effect of TAK-147 were greater in the presence of NGF, suggesting a synergistic action of TAK-147 and NGF. TAK-147 showed high affinity for sigma receptors, whereas tacrine and physostigmine did not. Haloperidol and ifenprodil, high-affinity sigma ligands, remarkably enhanced ChAT activity in the septal neurons. These results suggested that TAK-147 has NGF-like neurotrophic activity on central cholinergic neurons, not via AChE inhibition but possibly via an effect on sigma receptors [38] . Now we think that the neurotrophic action of TAK-147 may be partly reflected in its pharmacological effects, especially those produced by chronic administration in aged rats [26] . There is a large body of evidence indicating that the BF cholinergic neurons depend on nerve growth factor (NGF) for differentiation, function and survival [36] . NGF may have therapeutic potential in the treatment of AD and the results of a preliminary clinical study with intracranial infusion of NGF suggest the benefit of NGF [37] . However, NGF itself has limited therapeutic use because of its large molecular size. Compounds with low molecular weight and high blood-brain-barrier 
Conclusions
